The month ahead: August’s upcoming events
Jazz’s Chimerix buy faces its big test.
Jazz’s Chimerix buy faces its big test.
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
The players are vying in the CD19 x CD20 Car-T arena.
The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy.
The menin inhibitor battle shapes up with Kura, Syndax and J&J all now in phase 3.
Meanwhile, Ichnos Glenmark takes a different trispecific multiple myeloma approach.